Research
Hormonal
Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.
Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.
StrongSupportsmedium confidence
Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group.
Why this rating
Based on the large randomized controlled trial design.
Source
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Arun J. Sanyal et al. · New England Journal of Medicine · 2025
rct · n=1197Cited 618×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →